Detection of potential biomarkers CXCL9, CXCL10, CCL2, CCL 5, IL-37 and IL-38 in blood and urine for acute and chronic rejection after kidney transplantatio

• Conditions: T86.1; Kidney transplant failure and rejection

• Registration Number: DRKS00015435
• Lead Sponsor: Klinikum der Johann Wolfgang Goethe-Universität Frankfurt am Main

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-11-07
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

Group A:
Men and women over the age of 18, who receive a kidney allograft and have no signs for rejection. The earliest inclusion date is four weeks after kidney transplantation.
Group B:
Men and women over the age of 18, who receive a kidney allograft and have a rejection, which is confirmed by a kidney biopsy
Group C:
Men and women over the age of 18, who receive a kidney allograft and suffer from a CMV- or BKV-infection
Group D:
Men and women over the age of 18, after de novo kidney transplantation
Group K:
Healthy men and healthy women over the age of 18, who don’t receive a kidney allograft

Exclusion Criteria

exclusion criteria arise from inclusion criteria

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary endpoint of the study is the recording of the concentrations of the following molecules in the blood and urine of the study participants: CXCL9, CXCL10, CCL2, CCL5, IL-37 and IL-38. If additional potential biomarkers are investigated among the study participants, the recording of the concentrations of these additional potential biomarkers will be the primary endpoint.

Secondary Outcome Measures

Name	Time	Method
non-existent